Over the last 12 months, Mineralys Therapeutics insiders reported no purchases and 10 sales totaling $6.4M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 21, 2026 | Warren EricChief Commercial Officer · O | ▼ Sale | 7,438 | $26.87 | $200K | -16.2% | plan |
| Jul 17, 2026 | Rodman David MalcomChief Medical Officer · O | ▼ Sale | 416 | $26.53 | $11K | -0.8% | plan |
| Jul 15, 2026 | Rodman David MalcomChief Medical Officer · O | ▼ Sale | 20,407 | $27.28 | $557K | -28.4% | plan · 2 tranches |
| Jul 13, 2026 | Congleton JonChief Executive Officer · O·D | ▼ Sale | 10,700 | $27.24 | $291K | -1.7% | plan |
| Jul 9, 2026 | Rodman David MalcomChief Medical Officer · O | ▼ Sale | 2,171 | $30.3 | $66K | -3.6% | plan |
| Jun 30, 2026 | Congleton JonChief Executive Officer · O·D | ▼ Sale | 75,000 | $26.14 | $2.0M | -10.9% | plan · 2 tranches |
| Jun 26, 2026 | Warren EricChief Commercial Officer · O | ▼ Sale | 104,124 | $25.9 | $2.7M | -73.1% | plan |
| Jun 17, 2026 | Rodman David MalcomChief Medical Officer · O | ▼ Sale | 14,474 | $24.19 | $350K | -20.2% | plan · 2 tranches |
| Jun 17, 2026 | Karydas DaphneD | ▼ Sale | 3,000 | $25 | $75K | -32.6% | plan |
| Jun 12, 2026 | Rodman David MalcomChief Medical Officer · O | ▼ Sale | 8,519 | $24.2 | $206K | -11.8% | plan · 2 tranches |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MLYS feed.